Growth Hormone Treatment Clinical Trial
Official title:
Growth Hormone Replacement Therapy on Metabolic Effects in Patients With Fatty Liver Caused by Growth Hormone Deficiency After Pituitary GH Adenoma Surgery: A Monocentric, Prospective, Randomized, Parallel-controlled Clinical Study.
Growth Hormone (GH) is essential for maintaining fat, muscle, bone, and energy balance. Adult Growth Hormone Deficiency (GHD) affects about 0.3% of adults. GHD, common post-pituitary tumor surgery or radiotherapy, disrupts lipid metabolism, increasing triglycerides and low-density lipoprotein cholesterol while decreasing high-density lipoprotein cholesterol. This is especially severe in GH adenoma patients, whose lipid metabolism issues worsen post-surgery, increasing the risk of atherosclerosis. Fat accumulates in the liver first, making liver fat content a key early indicator of metabolic disorders, which can lead to diabetes and atherosclerosis. Early intervention is crucial as liver fat deposition in Nonalcoholic Fatty Liver Disease (NAFLD) is reversible. Recombinant human growth hormone can treat GHD-related lipid metabolism disorders, but research on its effects on liver fat in post-surgery GH adenoma patients is limited. The investigators plan to treat these patients with 1 mg/week of recombinant human growth hormone for 24 weeks, aiming to normalize insulin-like growth factor-1 levels. Liver fat content changes will be measured using proton magnetic resonance spectroscopy (1H MRS) and Fibroscan. Changes in weight, BMI, waist circumference, fasting blood glucose, blood lipids, and other metabolic factors will also be evaluated to assess treatment efficacy and safety. Zhongshan Hospital, affiliated with Fudan University, performs over 300 pituitary tumor surgeries annually, including 100 GH adenoma cases. The hospital has extensive experience and can enroll 40 patients. The Endocrinology Department excels in evaluating lipid metabolism disorders in NAFLD using non-invasive methods. As a major hospital in Shanghai, it has ample patients to meet study requirements. Detailed exit criteria and rescue plans have been established to address potential adverse events during the study.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Have fully understood the informed consent and signed the informed consent; - Age: 18-60 years old; - Patients diagnosed with adult growth hormone deficiency (AGHD) (GH stimulation test: GH peak =5ug/l or organic hypothalamic-pituitary disease =3 pituitary hormone deficiency with IGF-1 < -2SD) - Patients with pituitary growth hormone adenoma proved pathologically after surgery - Anterior pituitary hormone supplementation (except growth hormone) - The liver fat content was more than 11% after six months to two years of operation by proton magnetic resonance spectroscopy (1H MRS). - Those who have not taken lipid-regulating drugs (statins, Bates); - Blood pressure <150/95mmHg, did not take any antihypertensive drugs; Exclusion Criteria: - Have any of the following liver disease history: chronic hepatitis, cirrhosis, liver cancer, autoimmune liver disease, alcoholic liver disease, hereditary liver disease - Significant abnormal liver function: ALT or AST= 2 times the upper limit of normal; HBsAg (+), and/or HCV-Ab (+); - Patients with serum creatinine value =1.5mg/dL (133umol/L); - Patients with severe heart disease (patients with a history of myocardial infarction and heart failure and/or severe arrhythmia); - Patients with severe infection, other operations within 6 months, or severe trauma; - Alcohol consumption (alcohol): male =140g/week; Female =70g/week; - Poorly controlled diabetic patients: HbA1c >9.5% within three months; Or use hypoglycemic drugs that may affect liver histopathology, including pioglitazone, GLP-1, and DP-4 inhibitors; - Patients with allergy or intolerance to the same drug used in the trial; - In the next 1 year, there are pregnancy plans or breastfeeding patients or patients with mental disorders; - Patients who have participated in other clinical trials within 24 weeks. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Zhongshan Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Zhongshan Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the percentage of liver fat | To evaluate the effect of recombinant growth hormone replacement therapy on hepatic fat content in NAFLD patients with GHD after pituitary GH adenoma surgery | up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02987868 -
Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine
|
N/A | |
Recruiting |
NCT03431727 -
Acromegaly - Before and After Treatment
|
||
Completed |
NCT03038594 -
Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients
|
Phase 2/Phase 3 | |
Completed |
NCT03203356 -
Adrenal Function in GHD Children
|
N/A | |
Completed |
NCT02782221 -
Lipolytic Effects of GH in Human Subjects in Vivo
|
N/A | |
Completed |
NCT05195437 -
Evolution of the Quality of Life of Short Statured Children Treated With Growth Hormone : Evaluation at Adult Size
|
||
Completed |
NCT05105685 -
Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS
|
Phase 1/Phase 2 | |
Completed |
NCT04244123 -
Web-based Adherence Information Integrated Nurse-led Monitoring Clinic
|
||
Not yet recruiting |
NCT03005561 -
Detection of Difficulties and Improvement Compliance to Growth Hormone Treatment
|
N/A | |
Completed |
NCT03033121 -
Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children
|
Phase 3 | |
Not yet recruiting |
NCT05660356 -
Growth Hormone Deficiency in Mild Traumatic Brain Injury
|
Early Phase 1 | |
Active, not recruiting |
NCT00867971 -
Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?
|
N/A | |
Recruiting |
NCT05253287 -
Growth Hormone in Decompensated Liver Cirrhosis
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03091374 -
Impact of Recombinant Human Growth Hormone on HIV Persistence
|
Phase 2 | |
Not yet recruiting |
NCT02326610 -
Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae
|
Phase 2 | |
Recruiting |
NCT06103513 -
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
|
Phase 3 | |
Recruiting |
NCT04938466 -
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy
|
||
Recruiting |
NCT06037473 -
The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
|
||
Recruiting |
NCT05144035 -
A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants
|
Phase 4 | |
Recruiting |
NCT03878992 -
Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle
|
N/A |